Semax

Semax exerts its effects through multiple mechanisms of action. It has been shown to modulate the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), which are crucial for neuronal survival, growth, and plasticity. Semax also enhances the activity of the serotonergic and dopaminergic systems, neurotransmitters involved in mood regulation, motivation, and cognitive functions.

Additionally, Semax exhibits antioxidant and anti-inflammatory properties, protecting neurons from oxidative stress and inflammation-induced damage. It has been found to reduce the accumulation of beta-amyloid peptides, which are implicated in the pathogenesis of Alzheimer's disease. Semax also improves blood circulation in the brain, enhancing oxygen and nutrient delivery to neural tissues.

• Cognitive enhancement: Semax has been shown to improve memory, learning, and attention in various animal models and clinical trials. It may enhance cognitive performance in healthy individuals and those with cognitive impairments.
• Neuroprotection: Semax exhibits neuroprotective properties, reducing neuronal damage and promoting neuronal survival in the face of various insults, such as ischemia, trauma, and neurodegenerative diseases.
• Mood regulation: Semax has been investigated for its potential anxiolytic and antidepressant effects, possibly through its modulation of serotonergic and dopaminergic systems.
• Stroke recovery: Semax has shown promise in promoting functional recovery and reducing neurological deficits following ischemic stroke in animal models.
• Neurodegenerative disorders: Semax has been explored as a potential therapeutic agent for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, due to its neuroprotective and cognitive-enhancing properties.

Based on the available preclinical data, the most common side effects associated with Semax treatment include:

• Headache: Mild headaches have been reported in some studies, although these effects are generally transient.
• Dizziness: Some subjects have experienced mild dizziness during administration.
• Allergic reactions: In rare cases, allergic reactions may occur in sensitive individuals.

Note: The safety profile of Semax has not been fully established, and further clinical studies are needed to fully evaluate the potential for side effects and long-term safety of Semax in mammals.

Semax peptide is a promising research compound with potential cognitive-enhancing, neuroprotective, and mood-regulating properties. Its ability to modulate neurotrophic factors, neurotransmitter systems, and inflammatory processes has sparked interest in its therapeutic potential for various neurological disorders. While the results from preclinical studies and clinical trials are encouraging, further research is needed to fully elucidate its mechanisms of action, safety profile, and clinical applications. As a research chemical, Semax peptide offers a valuable tool for investigating the complexities of the brain and developing novel therapies for neurological conditions.

1. Glazova NY, Manchenko DM, Volodina MA, Merchieva SA, Andreeva LA, Kudrin VS, Myasoedov NF, Levitskaya NG. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats. Neuropeptides. 2021 Apr;86:102114.
2. Sciacca MFM, Naletova I, Giuffrida ML, Attanasio F. Semax, a Synthetic Regulatory Peptide, Affects Copper-Induced Abeta Aggregation and Amyloid Formation in Artificial Membrane Models. ACS Chem Neurosci. 2022 Feb 16;13(4):486-496.
3. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Grivennikov IA, Myasoedov NF. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006.
4. Medvedeva EV, Dmitrieva VG, Limborska SA, Myasoedov NF, Dergunova LV. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats. Mol Genet Genomics. 2017 Jun;292(3):635-653.
5. Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68.
6. Lebedeva IS, Panikratova YR, Sokolov OY, Kupriyanov DA, Rumshiskaya AD, Kost NV, Myasoedov NF. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018 Sep;165(5):653-656.
7. Dmitrieva VG, Povarova OV, Skvortsova VI, Limborska SA, Myasoedov NF, Dergunova LV. Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia. Cell Mol Neurobiol. 2010 Jan;30(1):71-9.
8. Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014 Mar 24;15:228.
9. Panikratova YR, Lebedeva IS, Sokolov OY, Rumshiskaya AD, Kupriyanov DA, Kost NV, Myasoedov NF. Functional Connectomic Approach to Studying Selank and Semax Effects. Dokl Biol Sci. 2020 Jan;490(1):9-11.
10. Inozemtsev AN, Bokieva SB, Karpukhina OV, Gumargalieva KZ, Kamensky AA, Myasoedov NF. Semax prevents learning and memory inhibition by heavy metals. Dokl Biol Sci. 2016 May;468(1):112-4.

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. Neither the products described nor the company are intended to diagnose, treat, cure, or prevent any disease.